Thrilled to congratulate everyone on Match Day, especially the newly matched @MDAndersonNews Hematology & Medical Oncology Fellowship Class of 2029! #EndCancer

What an incredible week at the ASCO/AACR Methods in Clinical Cancer Research Workshop! Grateful and inspired by all of the amazing fellows and mentors @ASCO @AACR #vailworkshop #PDG6 #colorectalcancer #CRC @sepideh_gholami @manjuggm @YoussefBouferra @MirLimMD @Guv_onc

Congratulations to the @MDAndersonNews trainees who received 2025 @ConquerCancerFd Young Investigator and Merit Awards for their contributions to cancer research! Extremely grateful for your hard work and commitment to our mission to #EndCancer. So well-deserved!

Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues @OncoAlert @AnnPartridgeMD @oncofertility Link: ascopubs.org/doi/10.1200/JCO…

Grateful for the opportunity to work with the incredible @VanMorrisMD on this phase I/II trial of encorafenib, cetuximab and nivolumab in pts with BRAF V600E mutated mCRC who progressed on prior treatment with BRAF EGFR targeted tx. - While the addition of Nivo did not seem to overcome resistance after progression on prior E C, there remains a role of E C N in the BRAF tx naive population

6. #BREAKWATER: Ph 3, Enco Cetux mFOLFOX vs SoC in BRAFV600E mCRC - ORR 61% vs 40% - Interim OS at 12mos 79.5% vs 66% - Gr≥3 AEs: 37.7% vs 34.6% - New SoC for BRAFV600E 7/8

Here’s the @TheLancet publication! 📝 #GI25 @OncoAlert thelancet.com/journals/lance…

#GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Panc Ca 4. #StarterNET: GEP-NET 5. #CM8HW: dMMR/MSI-H mCRC 6. #BREAKWATER: BRAFV600E mCRC 7. ctDNA: #BESPOKE SWOG80702 #OncTwitter #gism @ASCO 1/8

Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic? Pan-RAS inhibitor shows early/deep molecular response (and 36% response rate) for G12X mutated pancreatic cancer. (Significant AEs: rash, diarrhea, nausea, vomiting) dailynews.ascopubs.org/do/pa…

#GI25 BREAKWATER @skopetz changing the paradigm yet again! The true master of BRAF and colorectal targeted therapy. BRAF first line mCRC; n=236 on experimental arm Enco (BRAF) Cetux (EGFR) FOLFOX ORR 60% vs 40%! OS not yet reached!!! Durable responses and twice as high in experimental arm. Well tolerated, amazing design to tease out contribution of components. New standard of care in BRAF disease. @OncoAlert

Great data for pts w/ 2 line met anal cancer for pembrolizumab ficerafusp alfa (EGFR/TGFb bispecific) -ORR 29% & 41% 12-mo DFS=benefit in liver mets pCR for exceptional responder ! Exciting signal as combination immuotherapy in anal cancer! @MDAndersonNews #endcancer @BicaraTx

#GI25 @ASCO #LBA🌟 🚨CM8HW in dMMR #mCRC - the awaited nivo/ipi1 vs nivo PFS 🙌 📌 N=707 across all lines, 55% 1L, centrally confirmed 📌 PFS HR 0.62, p0.0003 👉3 yr PFS 68% v 51% 📌 ORR 71% vs 58% - PD 10% w/ combo 📌 safely reassuring🤙 ➡️nivo/ipi is the new SOC for dMMR mCRC ➡️reserve pembro if ineligle for CTLA4 …already in NCCN 🇺🇸 ESMO 🇪🇺… 🤞🇨🇦soon! @OncoAlert @coloncanada @ccranorg

Dr. @mgfakih with P2 BOT/BAL study in refractory MSS mCRC w/o liver mets (vs TAS-102 or rego). BOT/BAL 75mg ORR 19% vs 0% SOC. Responses seem durable (data not yet mature). #GI25

SOOOO proud of our @MDAndersonNews med onc star fellows @MichaelLaPelusa, @KelseyPanMD, & @MirLimMD presenting their research today on #crcsm day at @ASCO #GI25 ! Future is looking bright with their brilliant minds to #endcancer !

👉👉👉Superb clinic & research teams working together in #TeamPemm clinic #leusm #BPDCN #MPNSM this month ! @MDAndersonNews #endcancer | L➡️R @doctorpemm Michelle Golez RNTerri Saenz RN Rhona Pinsoy RN Dr .@MirLimMD Dr Kekejian, Rodney Haltom PA 🙌

Join us in congratulating our resident physicians who are preparing to pursue advanced training through fellowship programs in their chosen specialty! @UTSWIMchief @thomasjwang1 @DinoKazi @UTSWNews 📷

Thrilled to welcome the newest class of hematology/medical oncology fellows to @MDAndersonNews! Excited to work with all of you during training! #EndCancer

IPI NIVO after prior PD1/L1 in HCC? ➡️Retrospective series, half tx w/ prior BEV/ATEZO (no prior anti-CTLA4) ➡️ORR 22% (7/32) ➡️All responders to late line IPI NIVO had NONRESPONSE to prior PD1/L1 ncbi.nlm.nih.gov/pmc/article…

Very happy to be partnering with UT Southwestern Medical Center to provide our #NutritionEducation course to medical students in the ambulatory clerkship program! Welcome to those students who begin their nutrition course today! 🩺🍓 #MedEd #FoodAsMedicine #FoodIsMedicine #MedEd